ClinicalTrials.Veeva

Menu

Study Evaluating Venlafaxine ER in Children and Adolescents With Social Anxiety Disorder

Wyeth logo

Wyeth

Status and phase

Completed
Phase 3

Conditions

Social Anxiety Disorder

Treatments

Drug: Venlafaxine ER

Study type

Interventional

Funder types

Industry

Identifiers

NCT00238719
0600B4-389

Details and patient eligibility

About

To determine the anxiolytic efficacy, safety, and tolerability of a flexible-dose of venlafaxine extended release (ER) administered for 16 weeks in the treatment of children and adolescent outpatients with social anxiety disorder (generalized) in a placebo-controlled study.

Sex

All

Ages

8 to 17 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Male or female outpatient
  • 8-17 year old
  • diagnosis of Social Anxiety Disorder

Exclusion criteria

  • concomitant psychiatric or medical disorders which interfere with safety or assessment

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems